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Keratinocyte Growth Regulation
TRP-ed Up Over Downregulated
TRPV4?
Wolfgang Liedtke1, Jennifer Y. Zhang2, Russell P. Hall III2 and Martin Steinhoff3
This commentary on an exciting new study (Fusi et al., 2014) puts the finding of
TRPV4 downregulation in several nonmelanoma skin cancers into context. The
original paper points toward possible use of TRPV4 as dermatopathologic marker,
also toward the possibility that downregulated TRPV4 can affect biological
properties of the cancer, by enhancing, but also regulating tumor growth. As
calcium-permeable TRPV4 has recently been identified as UVB-receptor in skin
keratinocytes, where it regulates skin tissue injury and pain after UVB over-
exposure, it is discussed whether TRPV4 downregulation can also be found in
other non-UVB-exposed cancers.
Journal of Investigative Dermatology (2014) 134, 2310–2312. doi:10.1038/jid.2014.250
In this issue of JID, an exciting new study
by Daniela Massi’s and Romina Nassini’s
groups at the University of Florence, Italy,
shows that keratinocytes from precancer-
ous lesions and from malignant skin
cancers exhibit considerable downregu-
lation of TRPV4 ion channels (Fusi et al.,
2014). Because sweat glands and endo-
thelial cells function as endogenous
positive controls, their finding suggests
that TRPV4 immunolabeling could be
a novel tissue marker in several skin
cancers and could improve diagnostic
accuracy in dermatopathology. How-
ever, the approach’s specificity needs to
be confirmed by examining additional
controls such as proliferative noninflam-
matory lesions (e.g., seborrheic keratosis
and verruca vulgaris), as well as healthy
skin proximal to cancer. Such a broad
study would also allow investigators to
correlate clinical features of a cancer with
the extent of TRPV4 downregulation.
Relevance for other epithelial tumors
with TRPV4 expression in the epithelium
before tumorigenesis
The question arises whether TRPV4 down-
regulation is restricted to skin cancer,
whereas other cancers, in which TRPV4
shows physiological epithelial expres-
sion, might not share this regulation. If
this were so, then epidermis-specific
TRPV4 downregulation in neoplastic
(or hyperproliferative) epithelia might
be associated with UVB exposure. Skin
is often UVB exposed, but intra-oral,
esophageal, and colonic epithelia—all
of which express TRPV4—are not. In
other words, does TRPV4 downregula-
tion in epithelia selectively affect UVB
carcinogenesis? Moreover, is TRPV4
downregulation in skin cancer ultimately
caused by UVB exposure? Chronically
UVB-damaged epidermis will be rele-
vant, where initial studies have demon-
strated TRPV4 upregulation (Moore et al.,
2013).
Does downregulation of the UV receptor,
TRPV4, protect UVB-exposed
keratinocytes against calcium
overexposure—or is it only an
epiphenomenon?
We can now consider whether in kerati-
nocytes UVB exposure and downregula-
tion of expression of a channel that is
activated by UVB—TRPV4 (Moore et al.,
2013)—are linked in an autoregulatory
feedback loop. TRPV4 downregulation
would protect the cell against an over-
abundance of calcium, and, in the con-
text of UVB exposure, against (detrimental)
consequences of UVB-mediated inflamma-
tion (including neurogenic inflammation)
and tissue injury. However, because
keratinocytes’ TRPV4 expression normally
facilitates calcium influx, which is also
known to sustain the layered architecture
of the epidermis by regulating keratinocyte
proliferation and differentiation (Yuspa
et al., 1989), TRPV4 downregulation may
represent cause, effect, or coincidence.
First, TRPV4 downregulation might
enable dedifferentiation and uncontrol-
led growth of keratinocytes, thus leading
to a malignant phenotype. Alternatively,
it may be a regulatory response of
malignantly transformed cells. We
can entertain the concept that TRPV4
downregulation is a counter-regulatory
mechanism of the malignantly trans-
formed cell because the stratified archi-
tecture of cancerous epithelia has been
lost, and calcium influx would fuel
growth, migration, and metastasis of
(pre) cancerous cells. Finally, it may be
an epiphenomenon without critical rele-
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vance for the biological properties of the
lesion. The scientific community is now
positioned to probe into these questions.
Cellular events prompting
downregulation of TRPV4 expression in
epithelia vs. regulation in the opposite
direction in primary sensory neurons
Fusi et al. (2014) show that IL-8 and
other pro-inflammatory cytokines lead
to TRPV4 downregulation in HaCaT
cells: a transformed human keratino-
cyte cell line with resemblance to
keratinocyte cancer cells. Chen et al.
(2013) have uncovered the opposite
regulation of TRPV4 in inflammatory
trigeminal pain. In temporo-mandibular
joint inflammation there is upregula-
tion of TRPV4 in trigeminal ganglion
neurons. In the paper by Moore et al.
(2013), we noticed TRPV4 upregulation
in response to acute UVB-mediated
injury, which was also apparent in
chronic UVB photodermatitis. These
observations raise the following question:
at what point, coinciding with which
event during epidermal carcinogenesis,
will TRPV4 be downregulated in keratino-
cytes and by which gene-regulatory
mechanism(s)?
Future aims to elucidate the biological
role of TRPV4 regulation in skin
In future studies, we suggest that inves-
tigations be conducted to correlate the
expression levels of TRPV4 and other
TRP ion channels in keratinocytes with
clinical parameters, especially markers
of malignancy in non-melanoma skin
cancer. This applies also to acute and
chronic UVB-induced dermatoses, and
to precancerous states that can lead to
non-melanoma skin cancer, induced by
UVB, UVA, or chemical carcinogens.
Furthermore, does TRPV4 downregula-
tion correlate with the development of
early dysplasia, late dysplasia, and early
malignancy in UVB-induced epidermal
skin tumors? With respect to skin cancer
and other skin conditions, do TRPV4
expression levels correlate with the
impairment in barrier function (Denda
et al., 2007), presence of pain, pruritus,
and/or inflammation?
Chronically UVB-damaged skin
should be studied to determine whether
TRPV4 is upregulated (Moore et al.,
2013), or rather becomes repressed,
after exposure. It will be relevant to dete-
rmine the point at which this happens.
There is precedence for finding
altered TRPV4 regulation in dermatolo-
gical disease (Sulk et al., 2012), includ-
ing the RNA-seq database indicating a
downregulation of TRPV4 mRNA in
psoriasis (Li et al., 2014): a benign
inflammatory hyperproliferative skin
disease. These observations reiterate
the need to investigate these highly
relevant, yet also complex scientific
questions of TRPV4 regulation in
keratinocytes with appropriate care.
Therefore, a multipronged comparison
needs to be conducted: UVB-mediated
vs. non-UVB-mediated inflammatory
skin diseases vs. noninflammatory
proliferative disorders vs. precancerous
states vs. benign vs. malignant
keratinocyte-derived tumors. Cohorts
need to be sufficiently large to
conclusively determine the role of
TRPV4 expression. This approach
has to take into account mRNA and
protein abundance of TRPV4, and—
where feasible—its functional expres-
sion as a channel. Additional relevant
questions concern the identities
of the downstream signaling cascades
as well as the gene-regulatory events
upstream of TRPV4 gene expression.
With respect to the latter, is TRPV4
downregulation in skin cancer a (direct)
result of persistent inflammation,
chronic UVB exposure, or epithelial
proliferation, or is it caused by malig-
nant transformation?
Conclusion
We anticipate that the findings from
Nassini’s and Massi’s groups will pre-
cipitate discussion about mechanisms
underlying keratinocyte-derived skin
cancer growth: TRPV4 as a keratino-
cyte-derived UVB detector is downre-
gulated in these cells during tumor
progression, perhaps in a ‘‘protective’’
autoregulatory, local homeostatic
manner. The relevant mechanisms are
yet to be discovered. TRPV4 down-
regulation could lead to uncontrolled
tumor growth of keratinocytes; however,
it could also exert a more growth-
antagonistic role in cells that no
longer obey physiological growth and
differentiation.
Thus, we are curious whether rees-
tablishing TRPV4 expression in malignant
(or pre-malignant) skin keratinocytes
could be therapeutic, or whether it
would eventually aggravate dysregu-
lated growth and enhance the metastatic
capacity of keratinocyte malignancies
(see also the effect of TRPV4 activation
in human airway epithelia on activated
RAS and enhanced MMP-1 expression
(Li et al., 2009; 2011)).
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Clinical Implications
 Epidermal squamous cell and basal cell skin cancer: is TRPV4 channel
downregulation in keratinocytes a novel tumor marker?
 Relevance of TRPV4 ion channel function for skin carcinogenesis can now
be examined.
 This represents an intriguing observation, because TRPV4 in epidermal
keratinocytes is activated by UVB radiation, which causes direct tissue
injury and pain.
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Augmentation of Cutaneous Wound
Healing by Pharmacologic Mobilization
of Endogenous Bone Marrow Stem
Cells
Jakub Tolar1 and John A. McGrath2
Novel therapeutic tools to accelerate wound healing would have a major impact
on the overall burden of skin disease. Lin et al. demonstrate in mice that
endogenous bone marrow stem cell mobilization, produced by a pharmacologic
combination of AMD3100 and tacrolimus, leads to faster and better-quality
wound healing, findings that have exciting potential for clinical translation.
Journal of Investigative Dermatology (2014) 134, 2312–2314. doi:10.1038/jid.2014.209
Wound healing can be improved by using
medications already in clinical use to
mobilize endogenous bone marrow cells
There have been thorough and acceler-
ated efforts to improve skin wound
healing. These endeavors have been
motivated by the disappointing out-
comes of standard care for individuals
with extensive burns, diabetic and pres-
sure ulcers, and disfiguring scarring.
In this issue, Lin et al. (2014) take an
important step forward in the develop-
ment of a robust and widely applicable
treatment for cutaneous defects. They
report on a novel approach for boosting
the innate healing potential by which
blood cells are mobilized and engaged
in productive skin repair. What is
remarkable, significant, and new is that
their strategy engages lymphohemato-
poietic cells in skin repair by repur-
posing medications that are already in
use in clinical medicine.
Pedigree of ideas
All tissues are endowed with the capa-
city to repair themselves. However, they
differ greatly in the degree of injury that
they can withstand—with the peripheral
and central nervous systems able to
recover from only relatively small
insults, and with cutaneous and hema-
topoietic systems able to restore their
functions even after major injury.
Skin and bone marrow, however, do
not heal in the same way. Skin wounds
heal through a tightly orchestrated
sequence of skin stem cell activation,
with keratinocyte migration to, and
re-epithelialization of, the wound. By
contrast, reconstitution of the whole
lymphohematopoietic system is, in prin-
ciple, possible from a single hemato-
poietic stem cell. Thus, it has long been
believed that the major difference
between these two highly reparative
organ systems was that local mechan-
isms were operational in mucocuta-
neous tissue repair (after trauma, burn,
or surgical incision), whereas systemic
mechanisms regenerated hematopoiesis
(after viral infection, or whole-body
irradiation or chemotherapy in prepa-
ration for bone marrow transplantation).
The clinical utility of both drugs
used in the current study has been
proven in the practice of transplantation.
AMD3100 is used to release bone mar-
row cells into the peripheral blood,
where hematopoietic progenitors can
be collected and used in either auto-
logous or allogeneic hematopoietic cell
transplantation (Figure 1). Like the
closely related drug cyclosporine, tacro-
limus has been widely used to prevent
and treat rejection of solid-organ trans-
plants, as well as the major immune
complication of allogeneic hematopoie-
tic cell transplantation: graft-versus-host
disease. The mechanisms of action are
different. AMD3100 interferes with the
interaction of the CXC chemokine
receptor 4 (CXCR4) and its ligand
CXC motif chemokine 12 (CXCL12)
between hematopoietic and stromal
cells in the bone marrow (and other
tissues). Tacrolimus, on the other hand,
is a calcineurin inhibitor that (in much
higher doses than used in the
current study) inhibits calcium-depen-
dent T-cell activation and expansion.
Of interest, repurposing a calcineurin
inhibitor from an immunosuppre-
ssive agent to an endogenous stem cell
mobilizer (CD133þ hematopoietic and
endothelial progenitor cells in this
study) has been done before: cyclospor-
ine was first investigated as an
antifungal antibiotic in the early 1970s
(Borel, 1986).
The study by Lin et al. (2014) builds
upon a history of ideas, but especially
on the elegant work of Tamai et al.
(2011), who discovered a naturally
occurring bone marrow cell mobilizer
(high-mobility group box 1 protein) and
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